Welcome to the e-CCO Library!

P0660: Comparative Accuracy and Reliability of Handheld versus Cart-Based Ultrasound in assessing Inflammatory Bowel Disease Activity
Year: 2025
Source: ECCO'25
Authors: Khaingx7x7x7 M.M.(1x7x7x72x7x7x73)*;Fernandesx7x7x7 R.G.(1x7x7x72x7x7x73);Anx7x7x7 Y.K.(1x7x7x72x7x7x73);Baratyx7x7x7 B.(4);Bryantx7x7x7 R.V.(5x7x7x76);Ghalyx7x7x7 S.(7);Smithx7x7x7 R.L.(8);Srinivasanx7x7x7 A.(9x7x7x710x7x7x711);Hayx7x7x7 K.(12);Begunx7x7x7 J.(1x7x7x72x7x7x73);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0661: Effectiveness of upadacitinib for induction of remission in moderate-to-severe ulcerative colitis: real-world clinical outcomes appear independent of prior tofacitinib exposure
Year: 2025
Source: ECCO'25
Authors: Elosua Gonzalezx7x7x7 A.(1)*;Zabalzax7x7x7 L.(1);Vicuñax7x7x7 M.(1);Rubiox7x7x7 S.(1);Nantesx7x7x7 Ó.(1);Rodriguezx7x7x7 C.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0662: Comparative effectiveness and safety of upadacitinibx7x7x7 tofacitinibx7x7x7 and filgotinib in patients with Ulcerative Colitis: analysis of whole and propensity score-matched data
Year: 2025
Source: ECCO'25
Authors: Bertinx7x7x7 L.(1x7x7x72)*;Scarabellox7x7x7 D.(3);Zingonex7x7x7 F.(1);Savarinox7x7x7 E.V.(1);Barberiox7x7x7 B.(4);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0663: Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn’s disease
Year: 2025
Source: ECCO'25
Authors: Gaox7x7x7 X.(1)*;Caox7x7x7 Q.(2);Ranx7x7x7 Z.H.(3);Chenx7x7x7 Y.X.(4);Chenx7x7x7 Y.(5);Wenx7x7x7 Z.H.(6);Liux7x7x7 D.L.(7);Dingx7x7x7 J.(8);Zhongx7x7x7 J.(9);Liux7x7x7 F.(10);Shax7x7x7 W.H.(11);Anx7x7x7 P.(12);Wangx7x7x7 B.M.(13);Hux7x7x7 L.X.(14);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0664: Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
Year: 2025
Source: ECCO'25
Authors: Chaparrox7x7x7 M.(1)*;Hermidax7x7x7 S.(1);Zabalza San Martínx7x7x7 L.(2);Tosca Cuquerellax7x7x7 J.(3); de Castrox7x7x7 L.(4); Larrubia Domínguezx7x7x7 C.(5);Rodríguez-Lagox7x7x7 I.(6);Reygosa Castrox7x7x7 C.(7);Varela Trastoyx7x7x7 P.(8); Gargallo-Puyuelox7x7x7 C.J.(9);Ripoll Abadíax7x7x7 P.(10);Ruiz-Cerullax7x7x7 A.(11);Barreiro-de Acostax7x7x7 M.(12);de Franciscox7x7x7 R.(13);Gutiérrezx7x7x7 A.(14);Jiménezx7x7x7 N.(15);Pajares Villarroyax7x7x7 R.(16);Bujandax7x7x7 L.(17);Trapero Martínezx7x7x7 A.M.(18);Arias Garcíax7x7x7 L.(19);Camargo Camerox7x7x7 R.(20);Calafatx7x7x7 M.(21);Diz-Lois Palomaresx7x7x7 M.T.(22);Robledo Andrésx7x7x7 P.(23);Sampedrox7x7x7 M.J.(24);Ber Nietox7x7x7 Y.(25);Bermejox7x7x7 F.(26);Calvo Moyax7x7x7 M.(27);Casanovax7x7x7 M.J.(1);Ceballosx7x7x7 D.(28);Martín-Rodríguezx7x7x7 D.(29);Mesonerox7x7x7 F.(30);Zabanax7x7x7 Y.(31);Sanjosé Crespox7x7x7 A.(32);Sierra-Ausínx7x7x7 M.(33);Caballolx7x7x7 B.(34);Curieses Luengox7x7x7 M.(35);Giordanox7x7x7 A.(36);Domènechx7x7x7 E.(21); Gisbertx7x7x7 J.P.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0665: Long-term efficacy and dose intensification of ustekinumab in achieving clinicalx7x7x7 laboratoryx7x7x7 and endoscopic remission in Crohn’s disease.
Year: 2025
Source: ECCO'25
Authors: Dussiasx7x7x7 N.(1)*;Melottix7x7x7 L.(2);Vaniglix7x7x7 N.(1);Gionchettix7x7x7 P.(1);Rizzellox7x7x7 F.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0666: Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 study
Year: 2025
Source: ECCO'25
Authors: Schreiber x7x7x7 S.W.(1);Issacs x7x7x7 K.(2);Zhu x7x7x7 B.(3);Wu x7x7x7 J.(3);Keohane x7x7x7 A.(3);Redondo x7x7x7 I.(3);Owen x7x7x7 C.(3)*;Navabi x7x7x7 S.(4);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0667: Therapeutic Optimization of Biologic Therapy in Ulcerative Colitis: A Retrospective Analysis of Endoscopic and Biomarker Outcomes
Year: 2025
Source: ECCO'25
Authors: Bezziox7x7x7 C.(1x7x7x72);Bertinx7x7x7 L.(1x7x7x73)*;Ranuccix7x7x7 L.G.(1);Marconcinix7x7x7 G.(1);Busaccax7x7x7 A.(1);Dal Buonox7x7x7 A.(1);Gabbiadinix7x7x7 R.(1);Loyx7x7x7 L.(1);Armuzzix7x7x7 A.(1x7x7x72);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0668: Is there a @@Weekend Effect@@ on clinical outcomes in acute severe ulcerative colitis? A single centre retrospective analysis
Year: 2025
Source: ECCO'25
Authors: Mohamedrashedx7x7x7 M.(1);Yogakanthix7x7x7 S.(1);xux7x7x7 C.(1);Bartlettx7x7x7 R.(1);Chewx7x7x7 M.(1);Nedumannilx7x7x7 L.(1);Lucasx7x7x7 S.(1);Chauhanx7x7x7 A.(1);Lewisx7x7x7 D.(1);Kashkoolix7x7x7 S.(1);Gargx7x7x7 M.(1)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0669: Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s Disease
Year: 2025
Source: ECCO'25
Authors: Danesex7x7x7 S.(1)*;Sandsx7x7x7 B.E.(2);Afzalix7x7x7 A.(3);Hisamatsux7x7x7 T.(4);Armuzzix7x7x7 A.(5);Wolfx7x7x7 D.(6);Duvallx7x7x7 G.(7);Van Rampelberghx7x7x7 R.(8);Olurindex7x7x7 M.(9);Terryx7x7x7 N.A.(9);Yeex7x7x7 J.(9);Lix7x7x7 H.(9);Rosas Ballinax7x7x7 M.(10);D'Haensx7x7x7 G.(11);Rubinx7x7x7 D.T.(12);Panaccionex7x7x7 R.(13);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P066: CCR2-monocytes are essential for the resolution of inflammation and tissue repair in colitis.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Stakenborg, G. Goverse, G. Farro, P. J. Gomez-Pinilla, 
G. E. Boeckxstaens, G. Matteoli*

Created: Friday, 22 February 2019, 9:49 AM
P066: Exploration of critical molecules for optimizing treatment by analyzing inflammatory cytokines in the intestinal mucosa of patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Yokoyama, Y.(1);Yamakawa, T.(1);Hayashi, Y.(1);Kazama, T.(1);Hirayama, D.(1);Nakase, H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P066: Fibrostenotic phenotype of fibroblasts in Crohn's disease is dependent on tissue stiffness and reversed by LOX inhibition
Year: 2017
Source: ECCO '17 Barcelona
Authors:

de Bruyn J.*1, van den Brink G.1, Steenkamer J.1, Buskens C.2, Bemelman W.2, Meisner S.3, Muncan V.3, te Velde A.3, D'Haens G.4, Wildenberg M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P066: Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis
Year: 2022
Source: ECCO'22
Authors: Leibovitzh, H.(1);Nayeri, S.(2);Borowski, K.(2);Hernandez-Rocha, C.(1);Lee, S.H.(1);Turpin, W.(1);Stempak, J.(2);Sandhu, I.(2);Milgrom, R.(2);Smith, M.I.(2);Croitoru, K.(1);Hirschfield, G.M.(3);Gulamhusein, A.(3);Silverberg, M.S.(1);
Created: Friday, 11 February 2022, 3:52 PM
P066: ON104, a novel bioengineered antibody targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) shows efficacy in two distinct models of experimental colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ferhat, M.(1)*;Mangano, K.(2);Nicoletti, F.(2);Landlinger, C.(1);Michael, T.(1);
Created: Friday, 14 July 2023, 10:48 AM
P066: Pharmacologic inhibition of integrin αvβ6 causes tumour shrinkage in colitis associated mouse colon tumours
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Busenhart*, L. Hering, K. Atrott, E. Patsenker, F. Stickel, K. Bäbler, B. Weder, A. Wyss, G. Rogler, M. Spalinger, M. Scharl

Created: Thursday, 21 February 2019, 9:14 AM
P066: Validation of assay for detection of free soluble mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in human serum and cerebrospinal fluid
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Fernandez Ocana1, J. Y. Zhang2, B. R. Jones3, S. W. Martin2, M. Goetsch*4, H. Neubert1

Created: Friday, 22 February 2019, 9:41 AM
P067 Proteins citrullination and Crohn’s disease: PAD4 but not PAD2 is a strong marker of ileal inflammation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Dragoni1,2, B. Creyns2,3, G. De Hertogh4, B. Verstockt2,5, W.J. Wollants2, B.J. Ke2, L. Marcellis4, G. Matteoli2, A. D’Hoore6, A. Galli1, M. Ferrante2,5, S. Vermeire2,5

Created: Thursday, 30 January 2020, 10:12 AM
P0670: Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GRAVITI study
Year: 2025
Source: ECCO'25
Authors: Hartx7x7x7 A.(1)*;Hisamatsux7x7x7 T.(2);Steinwurzx7x7x7 F.(3);D’Haensx7x7x7 G.(4);Liux7x7x7 W.(5);Olurindex7x7x7 M.(6);Ngqawax7x7x7 P.(6);Yangx7x7x7 Z.(6);Merrallx7x7x7 E.(7);Terryx7x7x7 N.A.(6);Panaccionex7x7x7 R.(8);Sandsx7x7x7 B.E.(9);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0671: Supporting vedolizumab treatment throughout pregnancy: Insights from a population pharmacokinetic model
Year: 2025
Source: ECCO'25
Authors: Duvnjakx7x7x7 Z.(1x7x7x72)*;Steenholdtx7x7x7 C.(3x7x7x74);Skejøx7x7x7 C.(5);Baunwallx7x7x7 S.M.D.(5);Widigsonx7x7x7 E.S.K.(1x7x7x72);Korgaardx7x7x7 J.(5);Klassenx7x7x7 R.A.(6);Bolstadx7x7x7 N.(6);Kjeldsenx7x7x7 J.(4);Poulsenx7x7x7 A.(7x7x7x78);Kievitx7x7x7 L.(9);Larsenx7x7x7 L.(10x7x7x711);Munkholmx7x7x7 P.(12);Svenningsenx7x7x7 L.(13);Haderslevx7x7x7 K.V.(8);Wildtx7x7x7 S.(14x7x7x715);Vindx7x7x7 I.(14);Kelsenx7x7x7 J.(5x7x7x716);Abrantesx7x7x7 J.A.(17);Micheletx7x7x7 R.(1);Huisingax7x7x7 W.(2x7x7x718);Kloftx7x7x7 C.(1x7x7x72);Julsgaardx7x7x7 M.(5x7x7x716);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session